Potential Ebola Vaccine Was Shelved for Years Because There Was No Market for It

Thomas W. Geisbert of the University of Texas Medical Branch in Galveston helped develop a vaccine that was effective in preventing Ebola in monkeys. (Credit: Michael Stravato for The New York Times)
Thomas W. Geisbert of the University of Texas Medical Branch in Galveston helped develop a vaccine that was effective in preventing Ebola in monkeys. (Credit: Michael Stravato for The New York Times)

Almost a decade ago, scientists from Canada and the United States reported that they had created a vaccine that was 100 percent effective in protecting monkeys against the Ebola virus. The results were published in a respected journal, and health officials called them exciting. The researchers said tests in people might start within two years, and a product could potentially be ready for licensing by 2010 or 2011.

It never happened. The vaccine sat on a shelf. Only now is the vaccine undergoing the most basic safety tests in humans — with nearly 5,000 people dead from Ebola and an epidemic raging out of control in West Africa.

Its development stalled in part because Ebola was rare, and until now outbreaks had infected only a few hundred people at a time. But experts also acknowledge that the lack of follow-up on such a promising candidate reflects a broader failure to produce medicines and vaccines for diseases that afflict poor countries. Most drug companies have resisted spending the enormous sums needed to to develop products useful mostly to poor countries with little ability to pay for them.

Now, as the growing epidemic devastates West Africa and is seen as a potential threat to other regions as well, governments and aid groups have begun to open their wallets. A flurry of research to test drugs and vaccines is underway, with clinical trials starting for several candidates, including the vaccine produced nearly a decade ago. With no vaccines or proven drugs currently available, the stepped up efforts are a desperate measure to stop a disease that has defied traditional means of containing it.

“There’s never been a big market for Ebola vaccines,” said Thomas W. Geisbert, an Ebola expert here at the University of Texas Medical Branch in Galveston, and one of the developers of the vaccine that worked so well in monkeys. “So big pharma, who are they going to sell it to?” Dr. Geisbert added: “It takes a crisis sometimes to get people talking. ‘Ok. We’ve got to do something here.’ ”

Dr. James E. Crowe Jr., director of a vaccine research center at Vanderbilt University, said that academic researchers who develop a prototype drug or vaccine that works in animals often encountered a “biotech valley of death” in which no drug company would help them cross the finish line.

Up to that point, the research may have cost a few million dollars, but tests in humans and scaling up production can cost hundreds of millions, and bringing a new vaccine all the way to market typically costs $1 billion to $1.5 billion, Dr. Crowe said. “Who’s going to pay for that?” he asked.

Click here to continue reading…

SOURCE: 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s